EP
NMRA icon

Essential Partners’s Neumora Therapeutics NMRA Stock Holding History

Essential Partners’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30
Closed -$54 – 2946
2025
Q4 		$54 Sell
30
-660
-96% -$1.45K ﹤0.01% 2629
2025
Q3 		$1.26K Sell
690
-450
-39% -$727 ﹤0.01% 1953
2025
Q2 		$836 Buy
+1,140
New +$864 ﹤0.01% 1558

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Essential Partners's NMRA Position: Q1 2026 in Review

Essential Partners sold out of Neumora Therapeutics (NMRA) in Q1 2026, closing a stake of 30 shares — an estimated $54 sold.

Essential Partners first reported a position in NMRA in Q2 2025 and held it in 3 quarters. The position peaked at $1.26K in Q3 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Essential Partners reported no remaining Neumora Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Essential Partners sold 30 Neumora Therapeutics shares in Q1 2026, an estimated $54.
  • Essential Partners first reported a position in Neumora Therapeutics in Q2 2025 and held it in 3 quarters.
  • Essential Partners's Neumora Therapeutics position peaked at $1.26K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Essential Partners's 13F filing for Q1 2026, filed 21 May 2026.